Reata Announces Initiation of Investigator-Sponsored Study Evaluating Bardoxolone for Complications Associated with COVID-19
July 28 2020 - 6:45AM
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,”
or “we”), a clinical-stage biopharmaceutical company, today
announced that researchers at NYU Grossman School of Medicine
(“NYU”), led by Sripal Bangalore, MD, interventional cardiologist
and professor of Medicine, are initiating an Investigator-Sponsored
Trial (“IST”), known as BARCONA, to study the effect of bardoxolone
methyl (“bardoxolone”) in patients suffering from COVID-19.
At NYU’s request, Reata is providing drug supply for the
trial. NYU will be initiating the Phase 2 BARCONA study with
a primary endpoint of safety.
The severity of COVID-19 and the development of
systemic complications is associated with excessive, systemic
inflammation, which can result in dysfunction of the lungs,
kidneys, and other organs. Acute kidney injury (“AKI”) has
been reported to occur in up to 28% of all hospitalized COVID-19
patients and up to 72% of patients who do not survive
COVID-19. Bardoxolone and its analogs have demonstrated
anti-inflammatory activity in animal models of acute lung and
kidney injury and have shown improvements in kidney function in
multiple clinical trials that enrolled over 3,000 patients with
various forms of chronic kidney disease.
About Reata Pharmaceuticals,
Inc.
Reata is a clinical-stage biopharmaceutical
company that develops novel therapeutics for patients with serious
or life-threatening diseases by targeting molecular pathways
involved in the regulation of cellular metabolism and inflammation.
Reata’s two most advanced clinical candidates, bardoxolone
and omaveloxolone, target the important transcription factor Nrf2
that promotes the resolution of inflammation by restoring
mitochondrial function, reducing oxidative stress, and inhibiting
pro-inflammatory signaling. Bardoxolone and
omaveloxolone are investigational drugs, and their safety and
efficacy have not been established by any agency.
Contact:
Reata Pharmaceuticals, Inc.(972)
865-2219http://reatapharma.com
Investors:
Vinny JindalVice President, Corporate Communications and
Strategy(469)
374-8721ir@reatapharma.comhttp://reatapharma.com/contact-us/
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements,” including, without
limitation, statements regarding the success, cost and timing of
our product development activities and clinical trials, our plans
to research, develop and commercialize our product candidates, our
plans to submit regulatory filings, and our ability to obtain and
retain regulatory approval of our product candidates. You can
identify forward-looking statements because they contain words such
as “believes,” “will,” “may,” “aims,” “plans,” “model,” and
“expects.” Forward-looking statements are based on Reata’s
current expectations and assumptions. Because forward-looking
statements relate to the future, they are subject to inherent
uncertainties, risks, and changes in circumstances that may differ
materially from those contemplated by the forward-looking
statements, which are neither statements of historical fact nor
guarantees or assurances of future performance. Important
factors that could cause actual results to differ materially from
those in the forward-looking statements include, but are not
limited to, (i) the timing, costs, conduct, and outcome of our
clinical trials and future preclinical studies and clinical trials,
including the timing of the initiation and availability of data
from such trials; (ii) the timing and likelihood of regulatory
filings and approvals for our product candidates; (iii) whether
regulatory authorities determine that additional trials or data are
necessary in order to obtain approval; (iv) the potential market
size and the size of the patient populations for our product
candidates, if approved for commercial use, and the market
opportunities for our product candidates; and (v) other factors set
forth in Reata’s filings with the U.S. Securities and Exchange
Commission, including the detailed factors discussed under the
caption “Risk Factors” in its Annual Report on Form 10-K for the
fiscal year ended December 31, 2019. The forward-looking
statements speak only as of the date made and, other than as
required by law, we undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events, or otherwise.
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Apr 2023 to Apr 2024